Skip to main content

Table 1 (abstract A48). Safety Summary

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

  2 years of abatacept treatment 6-month follow-up period
Day 113 Day 477 Day 645 Day 729 Day 85 Day 168
2–5-year-old cohort
Anti-GAD+ 1 1 0 0 0 0
Anti-TPO+ 0 0 0 0 0 0
6–17-year-old cohort       
Anti-GAD+ 0 0 0 1 0 0
Anti-TPO+ 0 3 1 1 0 1
  1. Values in table are number of patients. *Autoantibody positivity was defined as anti-GAD ≥5 IU/mL or anti-TPO ≥60 U/mL. TSH abnormalities were defined as >1.5x ULN, or if baseline was >ULN then >2x baseline value. †One patient had new-onset positive anti-TPO antibodies on Days 477, 645, 729 and Day 168 during the follow-up period. ‡The patients with positive anti-GAD and anti-TPO at Day 729 are different patients. GAD=glutamic acid decarboxylase; TPO=thyroid peroxidase; TSH=thyroid-stimulating hormone; ULN=upper limit of normal